Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 16/20 | 1.00 |
| ▸ | ESR1 | P03372 | 2/20 | 0.70 |
| ▸ | AR | P10275 | 2/20 | 0.70 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.70 |
| ▸ | SHBG | P04278 | 2/20 | 0.70 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.70 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7070071 | 1.00 | CYP19A1 (1.00) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5697554 | 1.00 | CYP19A1 (1.00) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5499393 | 0.87 | CYP19A1 (0.77) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL9938719 | 0.85 | CYP19A1 (0.74) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL4448213 | 0.85 | CYP19A1 (0.74) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5479309 | 0.85 | CYP19A1 (0.74) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5574098 | 0.84 | CYP19A1 (0.73) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL5493314 | 0.84 | CYP19A1 (0.73) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL1418753 | 0.84 | CYP19A1 (0.73) | CYP19A1ESR1ARESR2SHBG | |
| SCHEMBL10405002 | 0.84 | CYP19A1 (0.72) | CYP19A1ESR1ARESR2SHBG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007030124-A2 | TREATMENT SCREENING METHODS | HOLLIS-EDEN PHARMACEUTICALS, INC (US) | 2007-03-15 | — | — | WO | claimed |
| EP-1677803-A2 | METHOD OF INHIBITING THE EXPRESSION OF A MULTI-DRUG RESISTANCE GENES AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES THEREBY ENHANCING THE EFFECTIVENESS OF CHEMOTHERAPEUTIC AGENTS TO TREAT CANCERS | Forbes Medi-Tech Inc. (CA) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005102357-A1 | COMPOSITIONS COMPRISING ONE OR MORE POLICOSANOLS AND/OR POLICOSANOIC ACIDS COMBINED WITH STEROL AND/OR STEROID BASED ASCORBIC ACID DERIVATIVES, AND USES THEREOF | FORBES MEDI-TECH INC. (CA) | 2005-11-03 | — | — | WO | disclosed |
| US-20050234025-A1 | Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof | FORBES MEDI-TECH INC. | 2005-10-20 | — | — | US | disclosed |
| WO-2005042692-A2 | A METHOD OF INHIBITING THE EXPRESSION OF GENES WHICH MEDIATE CELLULAR CHOLESTEROL INFLUX IN ANIMAL CELLS AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES USING CHOLESTEROL ABSORPTION INHIBITORS | FORBES MEDI-TECH INC. (CA) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005030225-A2 | METHOD OF INHIBITING THE EXPRESSION OF A MULTI-DRUG RESISTANCE GENES AND INHIBITING THE PRODUCTION OF PROTEINS RESULTING FROM THE EXPRESSION OF SUCH GENES THEREBY ENHANCING THE EFFECTIVENESS OF CHEMOTHERAPEUTIC AGENTS TO TREAT CANCERS | FORBES MEDI-TECH INC. (CA) | 2005-04-07 | — | — | WO | disclosed |
| EP-1513862-A2 | NOVEL DERIVATIVES OF ANDROSTANE AND ANDROSTENE WITH ASCORBIC ACID AND USE THEREOF IN TREATING OR PREVENTING VARIOUS CONDITIONS, DISEASES, AND DISORDERS | Forbes Medi-Tech Inc. (CA) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003104254-A2 | NOVEL DERIVATIVES OF ANDROSTANE AND ANDROSTENE WITH ASCORBIC A CID AND USE THEREOF IN TREATING OR PREVENTING VARIOUS CONDITIONS, DISEASES, AND DISORDERS | FORBES MEDI-TECH INC. (CA) | 2003-12-18 | — | — | WO | disclosed |
| US-20030232797-A1 | Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders | FORBES MEDI-TECH INC. | 2003-12-18 | — | — | US | disclosed |
| EP-0413269-B1 | 4-substituted 17-beta-(cyclopropyloxy)androst-5-EN-3-beta-OL and related compounds useful as C17-20 lyase inhibitors | MERRELL PHARMA INC (US) | 1996-06-05 | — | — | EP | disclosed |
| EP-0413269-A2 | 4-substituted 17-beta-(cyclopropyloxy)androst-5-EN-3-beta-OL and related compounds useful as C17-20 lyase inhibitors | MERRELL PHARMACEUTICALS INC. (US) | 1991-02-20 | — | — | EP | disclosed |
| US-4966897-A | 4-substituted 17β-(cyclopropyloxy)androst-5-en-3β-ol and related compounds useful as C17-20 lyase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-30 | — | — | US | disclosed |
| US-4179336-A | OXIDATIVE DEGRADATION OF ANDROSTANE STEROL 3-ACETAL | SCHERING AKTIENGELLSCHAFT (DE) | 1979-12-18 | — | — | US | disclosed |
| US-4170518-A | Microbiological conversion of sterol derivatives to 5-androsten-17-one derivatives and their use | SCHERING AKTIENGESELLSCHAFT (DE) | 1979-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234025-A1 | Compositions comprising one or more policosanols and/or policosanoic acids combined with sterol and/or steroid based ascorbic acid derivatives, and uses thereof | CYP27A1, CYP46A1, DHCR7 | CYP19A1 195/4885ESR1 3629/4885AR 1194/4885 |
| US-20030232797-A1 | Novel derivatives of androstane and androstene with ascorbic acid and use thereof in treating or preventing various conditions, diseases, and disorders | HSD17B11, CYP17A1, CYP27B1 | CYP19A1 17/4885ESR1 126/4885AR 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.